- Addressing the challenges of outsourced manufacturing as biopharma companies aim to enter global markets through capacity expansion and seek strong partnerships
- Highlighting the significance of planned growth to meet industry demand and Samsung Biologics’ proactive growth strategy to synergize for success through CDMO collaboration
- A CDMO’s Perspective: Strategizing for the future through diversification and portfolio augmentation, with a core focus on the development of an expanded range of therapies while concurrently bolstering capacity
—
Kevin Sharp
SVP, Head of Samsung Biologics America Sales
Samsung Biologics
Kevin Sharp is the Senior Vice President and Head of Samsung Biologics America Sales. He joined the company in 2017 and has served as the Head of Global Sales and Head of Alliance Management at Samsung Biologics. Kevin has held various commercial and business development positions in pharmaceutical companies in the U.S. throughout his career. Kevin was the Director of Business Development at Contract Pharmacal Corp and served over 9 years at GSK in multiple business development and procurement roles supporting their vaccines, pharmaceutical and consumer healthcare businesses. Kevin has completed the Executive Development Program at the Northwestern University Kellogg School of Management to enhance his business and leadership capabilities.
